Syngene International Limited (SYNGENE) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Syngene International Limited stock ₹647, price ₹441, upside +46.6%, quality 59 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Syngene International Limited
SYNGENE · NSECheap (32% below fair value) and solid company, but falling price: meets 2 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range ₹346.00 – ₹943.30 · fair‑value band ₹468.07 – ₹830.56 · the ₹441.20 price screens below the ₹646.63 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether Syngene International is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally.
Show moreShow less
The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services.
It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services.
In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization.
It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies.
The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.
Stock analysis
Syngene International Limited (SYNGENE) currently trades at ₹441.20, while our model-based Fair Value estimate is ₹646.63, implying the stock looks roughly 32% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of ₹247.89 per share, and 1 of the 26 models we run sit above the ₹441.20 price.
Bear case: the Asset-Based group reads lowest at ₹79.94, and 25 of the 26 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ₹468.07 (bear) to ₹830.56 (bull), the price of ₹441.20 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Syngene International Limited reported revenue of ₹37.4B in FY2026 versus ₹26.0B in FY2022, a compound +9.5%/yr. Reported net income was ₹3.2B in FY2026, compounding −5.4%/yr from FY2022.
Key figures
Market cap ₹178B (≈ $1.9B) Small · P/E ratio 95.5 · P/S ratio 5.04 · EPS (TTM) ₹4.62 · Dividend yield 0.3% · Net margin 5.3% · Return on equity 3.9% · Return on assets (EBIT) 17.9% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 41 out of 100 (low confidence).
What moves the price
The share trades about 33% below its 52-week high and 28% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −10% fair-value upside, at 47%, SYNGENE screens cheaper than that median.
Fair Value models
All 26 models by family
The fair value above starts from this blend and is adjusted for a year distorted by one-off effects.
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
Watch SYNGENE, get fair value alerts →
Compare Syngene International Limited with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 150 stocks
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- P/B ratio by industry
- Net margin by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| WuXi AppTec Co 603259 | ¥144.41 | ¥164.66 | +14% | vs SYNGENE |
| IQVIA Holdings IQV | $265.12 | $291.63 | +10% | vs SYNGENE |
| Illumina, Inc ILMN | $207.01 | $227.71 | +10% | vs SYNGENE |
| Thermo Fisher Scientific Inc TMO | $700.22 | $686.04 | −2% | vs SYNGENE |
| Danaher Corporation DHR | $233.02 | $209.18 | −10% | vs SYNGENE |
| IDEXX Laboratories, Inc IDXX | $704.23 | $496.48 | −30% | vs SYNGENE |
| Lonza Group LONN | CHF 670.20 | CHF 259.80 | −61% | vs SYNGENE |
| Mettler-Toledo International Inc MTD | $1,739 | $655.06 | −62% | vs SYNGENE |
| Agilent Technologies, Inc A | $173.96 | $64.53 | −63% | vs SYNGENE |
| Waters Corporation WAT | $460.25 | $91.26 | −80% | vs SYNGENE |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Syngene International Limited (SYNGENE) overvalued or undervalued?
What is the fair value of SYNGENE?
What is the quality score of SYNGENE?
What is the price target for Syngene International Limited (SYNGENE)?
What is the Syngene International Limited stock forecast for 2026?
What is the revenue of Syngene International Limited (SYNGENE)?
Does Syngene International Limited pay a dividend?
How much is the dividend of Syngene International Limited (SYNGENE) and when is the ex-dividend date?
What growth is priced into Syngene International Limited (SYNGENE)?
What discount rate (WACC) does the fair value of SYNGENE use?
What is a reverse DCF?
How much growth has Syngene International Limited (SYNGENE) delivered so far?
How fast is the sector of Syngene International Limited (SYNGENE) growing?
What is the free cash flow yield of Syngene International Limited (SYNGENE)?
What is the intrinsic value of Syngene International Limited (SYNGENE)?
Is Syngene International Limited stock overvalued or undervalued in 2026?
Is fair value the same as the market price of SYNGENE?
How much is Syngene International Limited worth?
What do the bullish and bearish scenarios say about SYNGENE?
What is the P/E ratio of SYNGENE?
How solid is the balance sheet of Syngene International Limited (SYNGENE)?
How far is SYNGENE from its 52-week high?
Which stocks are comparable to Syngene International Limited?
Is Syngene International Limited stock attractive at the current price?
How is the fair value of SYNGENE calculated?
Is it still worth investing in stocks now?
What is the share price of Syngene International Limited (SYNGENE)?
What should I pay attention to with Syngene International Limited right now?
Where does the earnings growth of Syngene International Limited (SYNGENE) come from?
Key figures of Syngene International Limited
How large is the market capitalisation of Syngene International Limited (SYNGENE)?
What is the P/S ratio of Syngene International Limited (SYNGENE)?
What are the earnings per share of Syngene International Limited (SYNGENE)?
What is the dividend yield of Syngene International Limited (SYNGENE)?
What is the net margin of Syngene International Limited (SYNGENE)?
What is the return on equity of Syngene International Limited (SYNGENE)?
What is the EBIT return on assets of Syngene International Limited (SYNGENE)?
What is the operating margin of Syngene International Limited (SYNGENE)?
How fast is revenue growing at Syngene International Limited (SYNGENE)?
How fast are earnings growing at Syngene International Limited (SYNGENE)?
How much net cash does Syngene International Limited (SYNGENE) hold?
Watch Syngene International Limited in the live analysis
One click puts Syngene International Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.